RAPT - RAPT Therapeutics, Inc.

QQQ $ 622.02 $ -1.26 (-0.2 %)

DIA $ 469.19 $ -1.23 (-0.26 %)

SPY $ 675.24 $ -0.89 (-0.13 %)

TLT $ 89.86 $ 0.08 (0.09 %)

GLD $ 362.22 $ -1.42 (-0.39 %)

Previous Close

$ 29.35

Open

$ 28.57

Bid

$ 28.47 x 26

Ask

$ 28.64 x 200

Day's Range

$ 28.57 - $ 28.57

52 Week Range

$ 5.67 - $ 42.39

Volume

359,847

Average Volume

Market Cap

485.38M

Beta (5Y Monthly)

$ 1.51

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-07-2025	06-30-2025	10-Q
2	05-08-2025	03-31-2025	10-Q
3	03-06-2025	01-01-1970	10-K
4	11-12-2024	09-30-2024	10-Q
5	08-08-2024	06-30-2024	10-Q
6	05-09-2024	03-31-2024	10-Q
7	03-07-2024	12-31-2023	10-K
8	11-13-2023	09-30-2023	10-Q
9	08-11-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-14-2023	12-31-2022	10-K
12	11-10-2022	09-30-2022	10-Q
13	08-11-2022	06-30-2022	10-Q
14	05-11-2022	03-31-2022	10-Q
15	03-10-2022	12-31-2021	10-K
16	11-10-2021	09-30-2021	10-Q
17	08-11-2021	06-30-2021	10-Q
18	05-11-2021	03-31-2021	10-Q
19	03-11-2021	12-31-2020	10-K
20	11-16-2020	09-30-2020	10-Q
21	08-13-2020	06-30-2020	10-Q
22	05-14-2020	03-31-2020	10-Q
23	03-30-2020	12-31-2019	10-K
24	12-11-2019	09-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Wells Fargo Maintains Overweight on RAPT T...
11/03/2025 14:11:17

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $...

HC Wainwright & Co. Maintains Buy on RAPT ...
10/27/2025 16:57:39

HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price targe...

Guggenheim Initiates Coverage On RAPT Ther...
10/27/2025 12:11:40

Guggenheim analyst Yatin Suneja initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Buy rating and announces Price ...

RAPT Therapeutics Initiates prestIgE Phase...
10/27/2025 12:07:40

Reported Earlier, RAPT Therapeutics Prices...
10/22/2025 07:27:34

RAPT Therapeutics Announces Common Stock O...
10/21/2025 20:02:32

RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on ...

Wells Fargo Maintains Overweight on RAPT T...
10/21/2025 13:08:18

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $...

Barclays Maintains Overweight on RAPT Ther...
10/21/2025 12:47:15

Barclays analyst Etzer Darout maintains RAPT Therapeutics (NASDAQ:RAPT) with a Overweight and raises the price target from $...

Clear Street Maintains Buy on RAPT Therape...
10/21/2025 11:35:21

Clear Street analyst Kaveri Pohlman maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $4...

JP Morgan Upgrades RAPT Therapeutics to Ov...
10/20/2025 21:58:58

JP Morgan analyst Anupam Rama upgrades RAPT Therapeutics (NASDAQ:RAPT) from Neutral to Overweight and raises the price targe...

12 Health Care Stocks Moving In Monday's I...
10/20/2025 18:39:30

Trading Halt: Halt status updated at 8:25:...
10/20/2025 12:25:08

RAPT Therapeutics And Shanghai Jeyou Annou...
10/20/2025 12:07:41

- RPT904 at both Q8W and Q12W dosing showed comparable efficacy and safety to omalizumab at Q4W dosing- Efficacy sustained at...

Trading Halt: Halted at 7:55:00 a.m. ET - ...
10/20/2025 11:55:04

why-delcath-systems-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket

Why Delcath Systems Shares Are Trading Hig...
10/20/2025 09:10:06

Reported Sunday, RAPT Therapeutics To Rele...
10/20/2025 07:33:49

Barclays Initiates Coverage On RAPT Therap...
10/13/2025 12:12:27

Barclays analyst Etzer Darout initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces P...

Clear Street Maintains Buy on RAPT Therape...
09/30/2025 12:27:23

Clear Street analyst Kaveri Pohlman maintains RAPT Therapeutics (NASDAQ:RAPT) with a Buy and raises the price target from $2...

RAPT Wins FDA Approval To Test Food Allerg...
09/29/2025 09:01:42

RAPT Therapeutics, Inc. (NASDAQ: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, dev...

Leerink Partners Upgrades RAPT Therapeutic...
09/26/2025 11:11:54

Leerink Partners analyst Thomas Smith upgrades RAPT Therapeutics (NASDAQ: RAPT) from Market Perform to Outperform and raises...